Clinical trials: Glaucoma
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Glaucoma
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
- Trial name
- NCT00716859
- Testing
- Timolol, latanoprost
- Where
- 48 sites in United States, Belgium and 18 more
- Volunteers
- 139 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Refractive Error, Glaucoma
A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products
Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.
- Conditions
- Refractive Error, Glaucoma, Cataracts, Clear Lens Exchange
- Trial name
- NCT05394324
- Testing
- Intervention
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 1,674 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Glaucoma, Ocular Hypertension
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.
- Trial name
- NCT00638742
- Testing
- latanoprost
- Where
- 13 sites in United States, Denmark and 4 more
- Volunteers
- 47 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00061529
- Testing
- Brimonidine Tartrate Ophthalmic Solution
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3…
- Trial name
- NCT01628601
- Testing
- Fixed combination 0.3 mg bimatoprost and 5 mg timolol
- Where
- Austria
- Volunteers
- 392 people
- Sponsor
- Allergan
Glaucoma
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients with glaucoma.
- Trial name
- NCT01426113
- Testing
- bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
- Where
- 9 sites in United States, France and 5 more
- Volunteers
- 6 people
- Sponsor
- Allergan
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma (OAG)
CyPass Clinical Experience Study
This study is to evaluate the long-term safety, effectiveness and clinical experience of the CyPass Micro-Stent in patients with glaucoma.
- Trial name
- CyCLE (NCT01097174)
- Testing
- CyPass Micro-Stent
- Where
- 14 sites in Austria, Bulgaria and 4 more
- Volunteers
- 555 people
- Sponsor
- Transcend Medical, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.
- Trial name
- NCT01637246
- Testing
- Any Fixed Combination Therapy
- Where
- Spain
- Volunteers
- 4,385 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan
Glaucoma, Open-Angle
A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years
This is an epidemiological, non-interventional, prospective study to collect data on glaucoma progression in a routine setting. Patients may receive treatment at the discretion of their physician per local standard of care.
- Trial name
- NCT01629407
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 315 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Survey of Patients Taking IOP-Lowering Eye Drops
Survey to assess perspectives of patients prescribed IOP-lowering eye drops at a single office visit.
- Trial name
- NCT02384772
- Testing
- Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01632423
- Testing
- bimatoprost 0.01%
- Where
- Germany
- Volunteers
- 10,337 people
- Sponsor
- Allergan
Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma…
- Conditions
- Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients
- Trial name
- NCT01652664
- Testing
- Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle
- Volunteers
- 184 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in…
- Trial name
- NCT01658839
- Testing
- Travoprost ophthalmic solution, 0.004% (new formulation)
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to…
- Trial name
- NCT01589510
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Austria
- Volunteers
- 419 people
- Sponsor
- Allergan
Glaucoma
Benchmarking Management of Glaucoma Using the Diopsys VEP/PERG Protocols.
Establish electrophysiological benchmarks, using the Diopsys Visual Evoked Potential/ Pattern ERG (VEP/PERG) protocols of populations with Glaucoma following: 1) Baseline VEP/ERG prior to treatment; and 2) VEP/PERG after…
- Trial name
- NCT02594280
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diopsys, Inc.
Open-angle Glaucoma (OAG)
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
This study is designed to collect clinical data at 3, 4, and 5 years postoperatively for participants who completed the CREST Study without having secondary IOP-lowering surgery in the study eye(s).
- Trial name
- CREST-XT (NCT07480343)
- Testing
- CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Iantrek, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00047554
- Testing
- Travoprost, 0.004% ophthalmic solution
- Volunteers
- 336 people
- Sponsor
- Alcon Research